TLSA vs. CNTX, GRFS, LVTX, MYNZ, NLSP, PHVS, PROC, QLI, ATNFW, and SXTPW
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), 180 Life Sciences (ATNFW), and 60 Degrees Pharmaceuticals (SXTPW). These companies are all part of the "medical" sector.
Tiziana Life Sciences (NASDAQ:TLSA) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, Tiziana Life Sciences had 7 more articles in the media than Context Therapeutics. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.67 beat Tiziana Life Sciences' score of 0.50 indicating that Context Therapeutics is being referred to more favorably in the news media.
14.0% of Context Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 9.4% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tiziana Life Sciences has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.
Context Therapeutics has a consensus price target of $4.00, indicating a potential upside of 190.70%. Given Context Therapeutics' higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Tiziana Life Sciences.
Tiziana Life Sciences received 86 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 58.82% of users gave Context Therapeutics an outperform vote.
Tiziana Life Sciences' return on equity of 0.00% beat Context Therapeutics' return on equity.
Summary
Tiziana Life Sciences beats Context Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
